Topical recombinant human thrombin in surgical hemostasis

Seminars in Thrombosis and Hemostasis

Volumn 36, Issue 5, 2010, Pages 477-484

  Bowman, Lyndsey J ^a   Anderson, Christopher D ^b   Chapman, William C ^b  

^a BARNES JEWISH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

antithrombin antibodies; hemostasis; recombinant thrombin; thrombin; Topical

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; HEMOSTATIC AGENT; HEPARIN; IODINE 125; RECOMBINANT HUMAN THROMBIN; THROMBIN DERIVATIVE; UNCLASSIFIED DRUG; RECOMBINANT PROTEIN; THROMBIN;

AMINO ACID SEQUENCE; ANTIBODY TITER; BLEEDING; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; HEMOSTASIS; HUMAN; HYPERSENSITIVITY; IMMUNOGENICITY; INFECTION; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; REVIEW; SEROCONVERSION; SURGICAL TECHNIQUE; THROMBOELASTOGRAPHY; THROMBOEMBOLISM; TREATMENT OUTCOME; VIRUS TRANSMISSION; ANIMAL; PROCEDURES;

ANIMALS; HEMOSTASIS, SURGICAL; HEMOSTATICS; HUMANS; RECOMBINANT PROTEINS; THROMBIN;

EID: 77954876755     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1255441     Document Type: Review

References (37)

1. 2006 National Hospital Discharge Survey. Hyattsville, MD National Center for Health Statistics Available at: http://www.cdc.gov/nchs/fastats/insurg.htm Accessed December 1, 2009
2. Shander A. Financial and clinical outcomes associated with surgical bleeding complications. Surgery 2007 142 (4, Suppl) S20-S25
3. Lynn M, Jeroukhimov I, Klein Y, Martinowitz U. Updates in the management of severe coagulopathy in trauma patients. Intensive Care Med 2002 28 (suppl 2) S241-S247
4. Dorion R P., Hamati H F., Landis B, Frey C, Heydt D, Carey D. Risk and clinical significance of developing antibodies induced by topical thrombin preparations. Arch Pathol Lab Med 1998 122 (10) 887-894
5. Carroll J F., Moskowitz K A., Edwards N M., Hickey T J., Rose E A., Budzynski A Z. Immunologic assessment of patients treated with bovine fibrin as a hemostatic agent. [see comment] Thromb Haemost 1996 76 (6) 925-931
6. Ortel T L., Mercer M C., Thames E H., Moore K D., Lawson J H. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 2001 233 (1) 88-96
7. Streiff M B., Ness P M. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion 2002 42 (1) 18-26
8. Thrombin-JMI [package insert]. King Pharmaceuticals, Inc November 2007
9. Lawson J H. The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost 2006 32 (Suppl 1) 98-110
10. EVITHROM [package insert]. OMRIX Biopharmaceuticals Ltd September 2007
11. Doria C, Fischer C P., Wood C G., Li P M., Marra S, Hart J. Phase 3, randomized, double-blind study of plasma-derived human thrombin versus bovine thrombin in achieving hemostasis in patients undergoing surgery. Curr Med Res Opin 2008 24 (3) 785-794
12. RECOTHROM [package insert]. ZymoGenetics, Inc Seattle, WA 2009
13. Hoffman M, Monroe D M. III. A cell-based model of hemostasis. Thromb Haemost 2001 85 (6) 958-965
14. Bishop P D., Lewis K B., Schultz J, Walker K M. Comparison of recombinant human thrombin and plasma-derived human alpha-thrombin. Semin Thromb Hemost 2006 32 (Suppl 1) 86-97
15. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. In: Pharmacology/Toxicology Review Memorandum BLA 125248 Thrombin (Recombinant); 2007. Accessed Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm120589.pdf Accessed October 5, 2009
16. Weaver F A., Lew W, Granke K, Yonehiro L, Delange B, Alexander W A., Study Investigators. A comparison of recombinant thrombin to bovine thrombin as a hemostatic ancillary in patients undergoing peripheral arterial bypass and arteriovenous graft procedures. J Vasc Surg 2008 47 (6) 1266-1273
17. Chapman W C., Lockstadt H, Singla N, Kafie F E., Lawson J H. Phase 2, randomized, double-blind, placebo-controlled, multicenter clinical evaluation of recombinant human thrombin in multiple surgical indications. J Thromb Haemost 2006 4 (9) 2083-2085
18. Chapman W C., Singla N, Genyk Y et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis [see comment]. J Am Coll Surg 2007 205 (2) 256-265
19. Hughes S D., Bishop P D., Garcia R, Zhang T, Alexander W A. Topical recombinant thrombin at a concentration of 1000 IU/mL reliably shortens in vivo TTH and delivers durable hemostasis in the presence of heparin anticoagulation and clopidogrel platelet inhibition in a rabbit model of vascular bleeding. Ann Surg Innov Res 2009 3 14
20. Greenhalgh D G., Gamelli R L., Collins J et al. Recombinant thrombin: safety and immunogenicity in burn wound excision and grafting. J Burn Care Res 2009 30 (3) 371-379
21. Heffernan J K., Ponce R A., Zuckerman L A. et al. Preclinical safety of recombinant human thrombin. Regul Toxicol Pharmacol 2007 47 (1) 48-58
22. Whitaker A N., McKay D G. Induction of hypotension in rhesus monkeys and rabbits by intravenous thrombin infusion. Lab Invest 1969 20 (1) 79-86
23. Gershon S K., Chang A C., Purvis W V., Salive M. Misadministration of topical bovine thrombin. JAMA 1999 282 (20) 1919
24. Cicala C, Bucci M, De Dominicis G, Harriot P, Sorrentino L, Cirino G. Bronchoconstrictor effect of thrombin and thrombin receptor activating peptide in guinea-pigs in vivo. Br J Pharmacol 1999 126 (2) 478-484
25. Uchigasaki S, Takahashi H, Suzuki T. A case of delayed death after accidental intravenous injection of thrombin. Int J Legal Med 1998 111 (4) 202-204
26. Pusateri A E., Holcomb J B., Bhattacharyya S N. et al. Different hypotensive responses to intravenous bovine and human thrombin preparations in swine. J Trauma 2001 50 (1) 83-90
27. Ofosu F A., Crean S, Reynolds M W. A safety review of topical bovine thrombin-induced generation of antibodies to bovine proteins. Clin Ther 2009 31 (4) 679-691
28. Nelsestuen G L., Suttie J W. The carbohydrate of bovine prothrombin. Partial structural determination demonstrating the presence of -galactose residues. J Biol Chem 1972 247 (19) 6096-6102
29. Mizuochi T, Yamashita K, Fujikawa K, Kisiel W, Kobata A. The carbohydrate of bovine prothrombin. Occurrence of Gal beta 1 leads to 3GlcNAc grouping in asparagine-linked sugar chains. J Biol Chem 1979 254 (14) 6419-6425
30. Nilsson B, Horne M K. III, Gralnick H R. The carbohydrate of human thrombin: structural analysis of glycoprotein oligosaccharides by mass spectrometry. Arch Biochem Biophys 1983 224 (1) 127-133
31. Schoenecker J G., Hauck R K., Mercer M C., Parker W, Lawson J H. Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose alpha1-3galactose. J Clin Immunol 2000 20 (6) 434-444
32. Lomax C. Safety of topical thrombins: the ongoing debate. Patient Saf Surg 2009 3 (1) 21
33. Terrab A, Pawlak D, Spaay P, Hoppensteadt D, Fareed J. Further removal of factor v related antigen from bovine thrombin by utilizing a membrane-filtration step. [see comment] Clin Appl Thromb Hemost 2008 14 (2) 135-140
34. Zhu H, Hoppensteadt D, Wahi R et al. Reduced immunogenic potential of membrane filtered bovine thrombin preparations for hemostatic application. Clin Appl Thromb Hemost 2009 15 (1) 32-40
35. Zhu H, Hoppensteadt D, Adiguzel C, Bick R L., Fareed J. Comparison of immunogenic potentials of bovine thrombin preparations. Clin Appl Thromb Hemost 2009 15 (1) 41-49
36. Singla N K., Ballard J L., Moneta G, Randleman C D. Jr, Renkens K L., Alexander W A. A phase 3b, open-label, single-group immunogenicity and safety study of topical recombinant thrombin in surgical hemostasis. J Am Coll Surg 2009 209 (1) 68-74
37. Physicians' Desk Reference. Red Book 2009. Montvale, NJ Physicians' Desk Reference 2009